BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,761.00
- Market cap
- ₹4,22,523 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 48.7×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries Management Change
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Other other announcement announcements
All →Lumino Industries Other Announcement
Lumino Industries intimated that its CIN and MCA listing status were updated after its BSE/NSE listing. This is a routine administrative compliance filing with no financial impact.
Aplab Other Announcement
Aplab confirmed zero deviation in utilizing its ₹6.29 Crore rights issue proceeds for Q3 FY27. This is a routine quarterly compliance certificate under SEBI ICDR.
Sathlokhar Synergys E&C Global Other Announcement
Sathlokhar Synergys filed its Q2 FY27 Reg 32 statement confirming no deviation in utilization of preferential issue proceeds. The company utilized ₹737.70 Cr of ₹932.36 Cr received, with no variation from stated objects.
Vardhman Special Steels Other Announcement
Vardhman Special Steels filed the Crisil Monitoring Agency Report for the quarter ended 30 September 2026. It reports no deviation from the preferential issue's use of proceeds.
Three M Paper Boards Other Announcement
Three M Paper Boards filed its Reg 13(3) investor grievance report. All complaint categories for the quarter show NIL figures.
Manika Plastech Other Announcement
Manika Plastech intimated a change in its CIN from U- to L-prefixed code following its September 2026 listing. This is a routine MCA registry update with no transactional or business substance.